GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Clinical trials for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple threat against stomach cancer: chemo, Low-Dose radiation, and immunotherapy
Disease control Not yet recruitingThis study tests whether adding low-dose radiation and an immunotherapy drug (tislelizumab) to standard chemotherapy improves outcomes for people with locally advanced stomach or gastroesophageal junction cancer. About 114 participants will be randomly assigned to receive either …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: Jiangsu Cancer Institute & Hospital • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New drug cocktail aims to wipe out stomach tumors before surgery
Disease control Not yet recruitingThis study tests a combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus chemotherapy and a targeted therapy (lenvatinib) in 20 people with a specific type of advanced stomach cancer (MSI-H/dMMR). The goal is to see if this treatment can shrink tumors enough …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New Two-Pronged attack on advanced stomach cancer enters testing
Disease control Not yet recruitingThis study is testing a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab, together called QL1706) with a modified chemotherapy regimen (TFOX) for people with advanced stomach or gastroesophageal junction cancer that is HER2-negative. The goal is to see if …
Matched conditions: GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC